citric acid, anhydrous has been researched along with Thrombocytopenia in 37 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The interruption may impair the solute clearance as it causes under dosing of CRRT." | 2.66 | Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. ( Akazawa, M; Fujii, T; Kataoka, Y; Nakata, Y; Takahashi, S; Tsujimoto, H; Tsujimoto, Y, 2020) |
| "The pseudo grey platelet syndrome is a rare artifact due to the degranulation of platelets caused, in vitro, by EDTA." | 1.46 | A case report of pseudo grey platelet syndrome with citrate-induced pseudothrombocytopenia: those artifacts may interfere in the platelet numeration and lead to critical misdiagnosis. ( Alamome, I; Bihl, PA; Ghiura, C; Herb, A; Hurstel, R; Maurer, M, 2017) |
| "Pseudothrombocytopenia was detected in 46 subjects." | 1.30 | Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia. ( Bartels, PC; Lombarts, AJ; Schoorl, M, 1997) |
| "A 72-year-old patient with multiple myeloma was admitted to the intensive care unit because of hypercalcemic crisis and acute renal failure." | 1.30 | Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia. ( Hora, P; Matĕjovic, M; Nalos, M; Novák, I; Pittrová, H; Rokyta, R; Srámek, V, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.11) | 18.7374 |
| 1990's | 12 (32.43) | 18.2507 |
| 2000's | 8 (21.62) | 29.6817 |
| 2010's | 10 (27.03) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J | 1 |
| Liu, Z | 1 |
| Zhao, T | 1 |
| Su, T | 1 |
| Jin, Q | 1 |
| Noel, MM | 1 |
| Feugray, G | 1 |
| Kasonga, F | 1 |
| Buchonnet, G | 1 |
| Daliphard, S | 1 |
| Barbay, V | 1 |
| Bera, E | 1 |
| Le Cam Duchez, V | 1 |
| Billoir, P | 1 |
| Tsujimoto, H | 1 |
| Tsujimoto, Y | 1 |
| Nakata, Y | 1 |
| Fujii, T | 1 |
| Takahashi, S | 1 |
| Akazawa, M | 1 |
| Kataoka, Y | 1 |
| Mirlashari, MR | 1 |
| Vetlesen, A | 1 |
| Nissen-Meyer, LSH | 1 |
| Naper, C | 1 |
| Tjønnfjord, GE | 1 |
| Njerve, IU | 1 |
| Ezligini, F | 1 |
| Landmark, BF | 1 |
| Meinke, S | 1 |
| Sandgren, P | 1 |
| Höglund, P | 1 |
| Hetland, G | 1 |
| Erkens, T | 1 |
| Van den Sande, L | 1 |
| Witters, J | 1 |
| Verbraeken, F | 1 |
| Looszova, A | 1 |
| Feyen, B | 1 |
| Herb, A | 1 |
| Maurer, M | 1 |
| Alamome, I | 1 |
| Bihl, PA | 1 |
| Ghiura, C | 1 |
| Hurstel, R | 1 |
| Brandenburger, T | 1 |
| Dimski, T | 1 |
| Slowinski, T | 1 |
| Kindgen-Milles, D | 1 |
| Aster, RH | 1 |
| Atalan, HK | 1 |
| Gucyetmez, B | 1 |
| Dumantepe, M | 1 |
| Berktas, M | 1 |
| Denizalti, TB | 1 |
| Tarhan, İA | 1 |
| Ozler, A | 1 |
| Pancione, Y | 1 |
| Fumi, M | 1 |
| Sale, S | 1 |
| Rocco, V | 1 |
| Bain, BJ | 1 |
| Trumper, C | 1 |
| Dumont, P | 1 |
| Goussot, V | 1 |
| David, A | 1 |
| Lizard, S | 1 |
| Riedinger, JM | 1 |
| Granat, F | 1 |
| Geffré, A | 1 |
| Braun, JP | 1 |
| Trumel, C | 1 |
| Lee, G | 1 |
| Arepally, GM | 1 |
| Braester, A | 1 |
| Jiménez, TM | 1 |
| Patel, SB | 1 |
| Pineda, AA | 1 |
| Tefferi, A | 1 |
| Owen, WG | 1 |
| Bolan, CD | 1 |
| Yau, YY | 1 |
| Cullis, HC | 1 |
| Horwitz, ME | 1 |
| Mackall, CL | 1 |
| Barrett, AJ | 1 |
| Malech, HL | 1 |
| Rehak, NN | 1 |
| Wayne, AS | 1 |
| Leitman, SF | 1 |
| Lau, LG | 1 |
| Chng, WJ | 1 |
| Liu, TC | 1 |
| Joannidis, M | 1 |
| Oudemans-van Straaten, HM | 1 |
| Schrezenmeier, H | 1 |
| Müller, H | 1 |
| Gunsilius, E | 1 |
| Heimpel, H | 1 |
| Seifried, E | 1 |
| Shimasaki, A | 1 |
| Kato, T | 1 |
| Ozaki, Y | 1 |
| Bartels, PC | 1 |
| Schoorl, M | 1 |
| Lombarts, AJ | 2 |
| Srámek, V | 1 |
| Novák, I | 1 |
| Matĕjovic, M | 1 |
| Rokyta, R | 1 |
| Nalos, M | 1 |
| Hora, P | 1 |
| Pittrová, H | 1 |
| Künstle, T | 1 |
| Maulhardt, S | 1 |
| Grünberger, M | 1 |
| Rothe, KF | 1 |
| Hidalgo, N | 1 |
| Hynes-Gay, P | 1 |
| Hill, S | 1 |
| Burry, L | 1 |
| Dworschak, M | 1 |
| Hiesmayr, JM | 1 |
| Lassnigg, A | 1 |
| Kuijpers, RW | 1 |
| Ouwehand, WH | 1 |
| Peelen, W | 1 |
| Michiels, JJ | 1 |
| Engelfriet, CP | 1 |
| von dem Borne, AE | 1 |
| Moon, RE | 1 |
| Fawcett, TA | 1 |
| Exposito, AJ | 1 |
| Camporesi, EM | 1 |
| Bennett, PB | 1 |
| Holthaus, J | 1 |
| Nagata, T | 2 |
| Tanaka, K | 1 |
| Suzuki, K | 1 |
| Minoura, T | 1 |
| Fujita, N | 1 |
| Nakanishi, S | 2 |
| Takahashi, H | 1 |
| Yoshimura, M | 1 |
| Mayan, H | 1 |
| Salomon, O | 1 |
| Pauzner, R | 1 |
| Farfel, Z | 1 |
| Shanwell, A | 1 |
| Sallander, S | 1 |
| Olsson, I | 1 |
| Gulliksson, H | 1 |
| Pedajas, I | 1 |
| Lerner, R | 1 |
| Mehta, RL | 1 |
| McDonald, BR | 1 |
| Ward, DM | 1 |
| García Suárez, J | 1 |
| Merino, JL | 1 |
| Rodríguez, M | 1 |
| Velasco, A | 1 |
| Moreno, MC | 1 |
| Casonato, A | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Shimada, N | 1 |
| de Kieviet, W | 1 |
| Gardella, S | 1 |
| Feliu, E | 1 |
| Labal, F | 1 |
| Casals, FJ | 1 |
| Rozman, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regional Citrate Versus Systemic Heparin Anticoagulation for Super High-flux Continuous Hemodialysis in Septic Shock: Effect on Middle Molecular Weight Molecules Clearances[NCT01839578] | 30 participants (Anticipated) | Interventional | 2013-05-31 | Recruiting | |||
| Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU = Multicentre, Controlled, Randomised Superiority Trial[NCT01962116] | Phase 3 | 405 participants (Actual) | Interventional | 2013-06-14 | Completed | ||
| Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin[NCT00286273] | Phase 4 | 215 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury[NCT02669589] | Phase 4 | 638 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients With Acute Renal Failure: A Randomized Clinical Trial[NCT00209378] | 139 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU[NCT01318811] | Phase 4 | 12 participants (Actual) | Interventional | 2011-03-31 | Terminated (stopped due to lack of recruitment) | ||
| Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial[NCT00798525] | Phase 4 | 70 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Supply of Lepirudin ended on 01. April 2012, thus trial terminated on 31. March 2012) | ||
| Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.[NCT00890214] | Phase 4 | 23 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates[NCT00965328] | Phase 4 | 14 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)[NCT02860130] | Phase 3 | 34 participants (Actual) | Interventional | 2016-09-27 | Terminated (stopped due to Study halted due to low recruitment, unrelated to safety or efficacy reasons) | ||
| Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial[NCT01269112] | Phase 4 | 103 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.[NCT01228292] | Phase 4 | 250 participants (Anticipated) | Interventional | 2011-01-31 | Not yet recruiting | ||
| [NCT02478242] | Phase 4 | 60 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.[NCT02194569] | 36 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| [NCT02423642] | 30 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming[NCT01486485] | Phase 3 | 160 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| [NCT01761994] | Phase 4 | 66 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Prismaflex Therapeutic Plasma Exchange: Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation[NCT04351438] | 108 participants (Actual) | Observational | 2012-01-31 | Active, not recruiting | |||
| Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies[NCT00562601] | 864 participants (Actual) | Observational | 1988-03-28 | Terminated (stopped due to Closed by the Sponsor/DSMB/IRB) | |||
| Built-in Calculator Optimizes Continuous Veno-venous Hemofiltration Prescription and Improves Therapeutic Quality in Critically-ill Acute Kidney Injury Patients[NCT05638711] | 1 participants (Actual) | Observational | 2019-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary endpoint for this study will be the difference in filter life in hours between the group receiving dilute heparin and the group receiving standard concentrated heparin. (NCT01318811)
Timeframe: 72 hours
| Intervention | hours (Mean) |
|---|---|
| Dilute Heparin | 22.46 |
| Standard Concentrated Heparin | 33 |
Information on major bleeding complications, and need for blood product transfusions will be collected. (NCT01318811)
Timeframe: 72 hours
| Intervention | clinical active major bleeding episodes (Number) |
|---|---|
| Dilute Heparin | 0 |
| Standard Concentrated Heparin | 0 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | beats/min (Mean) |
|---|---|
| Prismocitrate 18 | 2.1 |
| No Systemic Anticoagulation | 3.2 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | breaths/Min (Mean) |
|---|---|
| Prismocitrate 18 | -2.1 |
| No Systemic Anticoagulation | -1.1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | degree celsius (Mean) |
|---|---|
| Prismocitrate 18 | 0.2 |
| No Systemic Anticoagulation | -0.1 |
(NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | Hours (Mean) |
|---|---|
| Prismocitrate 18 | 0 |
| No Systemic Anticoagulation | 14.4 |
Training conducted on administration of Prismocitrate 18 to demonstrate the understanding of the user groups on how to use the solution by passing an assessment at the end of training. The user groups who needed to be assessed prior to use of Prismocitrate 18 in the clinical trial setting were to be comprised of physicians, nurses, and other clinicians who were part of prescribing, initiating or modifying treatment during the 120 hour Treatment Period. The training assessment was housed on a restricted access study website. Study personnel who completed the training assessment have a completion date listed which indicates that the individual received a passing score of 80% or better on the training assessment. (NCT02860130)
Timeframe: Prior to study use of Prismocitrate 18
| Intervention | site facility staff (Number) |
|---|---|
| Prismocitrate 18 | 6 |
(NCT02860130)
Timeframe: Up to 30 days post study CRRT treatment completion
| Intervention | Events (Number) |
|---|---|
| Prismocitrate 18 | 0 |
| No Systemic Anticoagulation | 1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 1.1 | 1.7 | 1.1 | 0.6 | 1.7 | 0.9 | 2.1 | 1.9 | 0.4 | 1.2 | 2.1 | -2.1 | 4 | 3.7 | 3.1 | 2.2 | -1.0 | 0.8 | -2.8 | -2.0 |
| Prismocitrate 18 | 0.4 | -1.3 | 0.3 | 2.4 | 1.3 | 3 | 2.8 | 2.4 | 1.3 | 3.7 | 3.2 | 3.6 | 2.5 | 4 | 3 | 3.5 | 1.6 | 3.5 | 2.7 | 2.8 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| No Systemic Anticoagulation | -6.4 | 2.8 |
| Prismocitrate 18 | 1.9 | -2.8 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Hour | 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -0.0 | -0.0 | -0.0 | -0.0 | -0.1 | -0.0 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | -0.2 | -0.1 | -0.1 | -0.2 | -0.1 |
| Prismocitrate 18 | -0.0 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 0.4 |
Systemic blood iCa concentrations (NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Hour | 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 hours | 60 hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0 | 0 | 0 | 0 | -0.0 | 0 | -0.0 | 0 | 0 | -0.0 | -0.0 | -0.0 | 0 | 0 | -0.0 | -0.0 | -0.0 | 0 | 0 | 0 | -0.0 |
| Prismocitrate 18 | -0.1 | -0.1 | -0.0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | -0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | pH (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0.1 | 0.1 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0.1 | -0.0 | 0 |
| Prismocitrate 18 | -0.0 | -0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | -0.0 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -2.3 | -3.5 | -2.2 | -2.9 | -3.6 | -4 | -3.5 | -2.8 | -3.2 | -2.3 | -3.2 | 0 | -2.0 | -3.0 | -2.1 | -1.7 | -1.7 | 0.6 | 0.7 | -1.2 |
| Prismocitrate 18 | 0.6 | 0.6 | 0.2 | -0.5 | 1.6 | 0.5 | 0.7 | 0.7 | 0.3 | 0.4 | 1.1 | 1 | 0.7 | 0.8 | 0.8 | 1.6 | 1.5 | 0.8 | 1 | -0.3 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 2.4 | 2.9 | 2.3 | 2 | 2.9 | 2.6 | 3.6 | 2.4 | 2.1 | 2.4 | 2.6 | 0.1 | 2.9 | 2.5 | 2.2 | 1.4 | -1.1 | -0.4 | -2.8 | -1.5 |
| Prismocitrate 18 | 0.2 | 0.8 | 1.3 | 2.8 | 2.9 | 3.3 | 3.3 | 2.7 | 2.7 | 4.7 | 3.7 | 4.2 | 2.8 | 3.3 | 3.3 | 2.8 | 2.2 | 2.7 | 3.8 | 2.8 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0.6 | 0.9 | 0.8 | 1.3 | 1.1 | 0.6 | 0.5 | 1.3 | 0.9 | 1 | 1 | 1.7 | 2.4 | 2.1 | 2.3 | 2.4 | 2.6 | 1.3 | 1.1 | 1 |
| Prismocitrate 18 | -1.9 | -3.4 | -3.9 | -3.9 | -5.5 | -5.0 | -4.9 | -5.1 | -5.4 | -5.9 | -5.3 | -5.6 | -5.5 | -5.8 | -5.9 | -6.2 | -6.0 | -5.9 | -7.7 | -8.1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0 | -0.0 | 0 | -0.0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0.1 | 0.1 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Prismocitrate 18 | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | -0.1 | -0.2 | -0.2 | -0.2 | -0.1 | -0.1 | -0.1 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.1 | -0.2 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -0.4 | -0.4 | -0.4 | -0.4 | -0.5 | -0.4 | -0.5 | -0.4 | -0.4 | -0.4 | -0.4 | -0.2 | -0.4 | -0.4 | -0.3 | -0.5 | -0.4 | -0.4 | 0.2 | -0.2 |
| Prismocitrate 18 | -0.3 | -0.3 | -0.5 | -0.7 | -0.6 | -0.7 | -0.8 | -0.9 | -0.8 | -0.9 | -0.8 | -0.8 | -0.8 | -0.8 | -0.8 | -0.8 | -0.7 | -0.8 | -0.9 | -0.8 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -0.1 | -0.1 | -0.1 | -0.2 | -0.1 | -0.0 | -0.0 | -0.0 | 0.1 | 0.1 | 0.3 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0 | 0.1 | 0.2 | 0.1 |
| Prismocitrate 18 | -0.4 | -0.4 | -0.7 | -0.9 | -0.9 | -1.0 | -1.0 | -1.0 | -1.2 | -1.2 | -1.2 | -1.2 | -1.2 | -1.3 | -1.4 | -1.1 | -1.2 | -1.2 | -1.5 | -1.1 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | 0.4 | -0.1 | 0.5 | 0.4 | 0.4 | -0.3 | -0.4 | 1.2 | 0.5 | 1 | 0.3 | 2.5 | 2.6 | 1.7 | 2.2 | 2.3 | 1.1 | 0.7 | 1.4 | 1 |
| Prismocitrate 18 | -1.1 | -1.6 | -1.7 | -1.7 | -1.9 | -1.1 | -0.7 | -1.5 | -1.3 | -1.3 | -0.7 | -0.8 | -1.8 | -2.2 | -1.8 | -2.0 | -1.8 | -2.4 | -2.8 | -3.7 |
(NCT02860130)
Timeframe: Baseline and up to 120 hours post CRRT treatment initiation
| Intervention | ratio (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Hour | 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 Hours | 60 Hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| No Systemic Anticoagulation | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 |
| Prismocitrate 18 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 |
Evaluates the efficacy of using Prismocitrate 18 in delivering the prescribed CRRT dose, with delivered dose based on (daily) average effluent rate divided by (daily) average weight and expressed as mL/kg/hour. (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | mL/kg/hour (Mean) | ||||
|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | |
| No Systemic Anticoagulation | 30.34 | 32.49 | 32.29 | 35.19 | 33.31 |
| Prismocitrate 18 | 32.3 | 33.12 | 31.62 | 31.93 | 32.83 |
Post-filter blood iCa concentrations will only be measured in the Prismocitrate 18 arm. The extracorporeal circuit (post-filter). (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | mmol/L (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Hour | 6 Hours | 12 Hours | 18 Hours | 24 Hours | 30 Hours | 36 Hours | 42 Hours | 48 Hours | 54 hours | 60 hours | 66 Hours | 72 Hours | 78 Hours | 84 Hours | 90 Hours | 96 Hours | 102 Hours | 108 Hours | 114 Hours | 120 Hours | |
| Prismocitrate 18 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 |
(NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | Events (Number) | |||
|---|---|---|---|---|
| Gastrointestinal | M150 filter | ostomy and rectum | upper Gastrointestinal tract | |
| No Systemic Anticoagulation | 4 | 1 | 1 | 1 |
| Prismocitrate 18 | 1 | 0 | 0 | 0 |
(NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | participants (Number) | |
|---|---|---|
| 3 Transfusions | 27 Transfusions | |
| No Systemic Anticoagulation | 2 | 1 |
| Prismocitrate 18 | 1 | 0 |
(NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| 0 Bleeding Events | 1 Bleeding Events | 2 Bleeding Events | 4 Bleeding Events | |
| No Systemic Anticoagulation | 13 | 3 | 0 | 1 |
| Prismocitrate 18 | 16 | 1 | 0 | 0 |
"The point estimate is time point (number of hours of the extracorporeal circuit life of a filter) at which (100-percentile)% filters are still surviving (i.e. number surviving divided by number at risk), based on the Kaplan-Meier method. For example, for the 25th percentile: after 33.18 hours, 75% of filters are still surviving. Given the early termination, this study was not powered to show statistically significant changes in efficacy endpoints. The Prismaflex M150 Set extracorporeal circuit life of filters were intended to be assessed over a maximum of 120 hours (Treatment Period) by duration of time for which each Prismaflex M150 Set could be used continuously over a maximum 72 hour time-period in each patient. The end of the extracorporeal circuit life was defined by the occurrence of one or both of the following Prismaflex® System alarms/conditions if the alarms could not be mitigated: (1) Warning: Filter Clotted, and/or (2) Advisory transmembrane pressure (TMP) Too High." (NCT02860130)
Timeframe: Up to 120 hours post CRRT treatment initiation
| Intervention | hours (Number) | ||
|---|---|---|---|
| 25 Percentile | 50 Percentile | 75 Percentile | |
| No Systemic Anticoagulation | 17.680 | 29.660 | NA |
| Prismocitrate 18 | 33.180 | NA | NA |
5 reviews available for citric acid, anhydrous and Thrombocytopenia
| Article | Year |
|---|---|
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Bias; Blood Coagulation; Catheter Obstruction; Citric Acid; Con | 2020 |
Renal replacement therapy and anticoagulation.
Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Critical Illness; Hemorrhage; Heparin; Humans; Int | 2017 |
Anticoagulation techniques in apheresis: from heparin to citrate and beyond.
Topics: Anticoagulants; Blood Component Removal; Calcium; Citric Acid; Hemorrhage; Heparin; Humans; Hypocalc | 2012 |
Clinical review: Patency of the circuit in continuous renal replacement therapy.
Topics: Anticoagulants; Blood Coagulation; Catheters, Indwelling; Citric Acid; Equipment Failure Analysis; H | 2007 |
Anticoagulation in continuous renal replacement therapy.
Topics: Anticoagulants; Citric Acid; Heparin; Heparin, Low-Molecular-Weight; Humans; Renal Replacement Thera | 2001 |
32 other studies available for citric acid, anhydrous and Thrombocytopenia
| Article | Year |
|---|---|
Thromboelastography and Traditional Coagulation Testing in Non-ICU-Admitted Patients with Acute Kidney Injury: An Observational Cohort Study.
Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Cohort Studies; Fibrinogen; Heparin; Humans; Throm | 2023 |
Stability over time of immature platelet fraction and comparison between EDTA and citrated whole blood samples.
Topics: Blood Platelets; Citrates; Citric Acid; Edetic Acid; Humans; Platelet Count; Thrombocytopenia | 2023 |
HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
Topics: Antibodies; Blood Grouping and Crossmatching; Blood Platelets; Citric Acid; Female; Histocompatibili | 2021 |
Effect of time and temperature on anticoagulant-dependent pseudothrombocytopenia in Göttingen minipigs.
Topics: Animals; Anticoagulants; Blood Specimen Collection; Citric Acid; Edetic Acid; Female; In Vitro Techn | 2017 |
A case report of pseudo grey platelet syndrome with citrate-induced pseudothrombocytopenia: those artifacts may interfere in the platelet numeration and lead to critical misdiagnosis.
Topics: Anticoagulants; Artifacts; Blood Platelets; Citric Acid; Diagnostic Errors; Female; Gray Platelet Sy | 2017 |
Blood platelet kinetics and platelet transfusion.
Topics: Anticoagulants; Blood Platelets; Blood Specimen Collection; Citric Acid; Glucose; History, 20th Cent | 2013 |
The combined use of pumpless extracorporeal lung assist and continuous arteriovenous hemofiltration with citrate anticoagulation in polytrauma patients.
Topics: Anticoagulants; Calcium Chelating Agents; Citric Acid; Extracorporeal Membrane Oxygenation; Hemofilt | 2015 |
Gray platelets - artifact or real?
Topics: Anticoagulants; Antigens, Surface; Artifacts; Autoantibodies; Blood Platelets; Blood Specimen Collec | 2016 |
Citrate anticoagulation in the ICU: the Leeds experience.
Topics: Acute Kidney Injury; Anticoagulants; Citric Acid; Critical Illness; England; Hemorrhage; Heparin; Hu | 2016 |
Identification and validation of a factor of commutability between platelet counts performed on EDTA and citrate.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Artifacts; Citric Acid; Diagnostic Errors; Edetic Ac | 2017 |
Comparison of platelet clumping and complete blood count results with Sysmex XT-2000iV in feline blood sampled on EDTA or EDTA plus CTAD (citrate, theophylline, adenosine and dipyridamole).
Topics: Adenosine; Animals; Blood Cell Count; Cat Diseases; Cats; Citric Acid; Dipyridamole; Edetic Acid; Fl | 2011 |
Pseudothrombocytopenia as a pitfall in the treatment of essential thrombocythemia.
Topics: Adult; Aged; Agglutinins; Anticoagulants; Artifacts; Autoantibodies; Citric Acid; Diagnosis, Differe | 2003 |
Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility.
Topics: ABO Blood-Group System; Anticoagulants; Antineoplastic Agents; Blood Component Removal; Blood Donors | 2003 |
Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens.
Topics: Adolescent; Anticoagulants; Blood Component Removal; Blood Donors; Blood Volume; Body Constitution; | 2004 |
Transfusion medicine illustrated. Unnecessary transfusions due to pseudothrombocytopenia.
Topics: Anticoagulants; Artifacts; Citric Acid; Diagnostic Errors; Edetic Acid; Female; Heart Block; Humans; | 2004 |
Anticoagulant-induced pseudothrombocytopenia and pseudoleucocytosis.
Topics: Anticoagulants; Antigens, CD; Artifacts; Cell Aggregation; Citrates; Citric Acid; Diagnostic Errors; | 1995 |
[Studies of platelet aggregation in six cases of EDTA-dependent pseudothrombocytopenia].
Topics: Adolescent; Adult; Aged; Anticoagulants; Citrates; Citric Acid; Dinoprostone; Edetic Acid; Female; H | 1994 |
Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia.
Topics: Anticoagulants; Blood Platelets; Cell Size; Chelating Agents; Citric Acid; Diagnostic Errors; Edetic | 1997 |
Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure, hypercalcemia, and thrombocytopenia.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Chelating Agents; Citric Acid; Hemodiafiltration | 1998 |
[Heparin-induced thrombocytopenia and hemofiltration: regional anticoagulation with sodium citrate].
Topics: Anticoagulants; Citric Acid; Extracorporeal Circulation; Hemofiltration; Heparin; Humans; Kidney Fai | 2000 |
Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
Topics: Anticoagulants; Chondroitin Sulfates; Citric Acid; Dermatan Sulfate; Dose-Response Relationship, Dru | 2002 |
Thrombocytopenia due to platelet glycoprotein IIb/IIIa-reactive autoantibodies non-reactive with platelets from EDTA blood.
Topics: Adult; Autoantibodies; Blood Platelets; Citrates; Citric Acid; Edetic Acid; Female; Humans; Infant, | 1992 |
Platelet count in deep saturation diving.
Topics: Citrates; Citric Acid; Diving; Fluorocarbons; Hematocrit; Heparin; Humans; Platelet Count; Prevalenc | 1992 |
[Anticoagulants preventing pseudo-thrombocytopenia].
Topics: Anticoagulants; Citrates; Citric Acid; Depression, Chemical; Edetic Acid; Humans; Platelet Aggregati | 1992 |
EDTA-induced pseudothrombocytopenia.
Topics: Angina, Unstable; Citrates; Citric Acid; Edetic Acid; Heparin; Humans; Male; Middle Aged; Platelet C | 1992 |
An alloimmunized, thrombocytopenic patient successfully transfused with acid-treated, random-donor platelets.
Topics: Blood Component Transfusion; Blood Platelets; Citrates; Citric Acid; Graft Survival; Histocompatibil | 1991 |
Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months.
Topics: Acute Kidney Injury; Citrates; Citric Acid; Evaluation Studies as Topic; Hemofiltration; Hemorrhage; | 1991 |
[Pseudothrombocytopenia: incidence, causes and methods of detection].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Artifacts; Blood Platelets; Child; Citrates; Citric Acid | 1991 |
Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease patient.
Topics: Adult; Antibodies, Monoclonal; Anticoagulants; Bleeding Time; Blood Platelets; Citrates; Citric Acid | 1990 |
[Studies on application of anticoagulants for the platelet counting of the patient with pseudothrombocytopenia].
Topics: Blood Specimen Collection; Citrates; Citric Acid; Edetic Acid; Humans; Platelet Count; Thrombocytope | 1987 |
Recognition and prevention of pseudothrombocytopenia and concomitant pseudoleukocytosis.
Topics: Anticoagulants; Blood Specimen Collection; Citrates; Citric Acid; Diagnostic Errors; Edetic Acid; Gl | 1988 |
[Pseudothrombocytopenia caused by EDTA; a possible cause of an erroneous diagnosis of Werlhof's disease].
Topics: Adult; Citrates; Citric Acid; Diagnostic Errors; Edetic Acid; Female; Humans; Male; Middle Aged; Pla | 1985 |